Aevi Genomic Medicine, Inc. (GNMX) Stock Rating Reaffirmed by Jefferies Group LLC
Jefferies Group LLC restated their hold rating on shares of Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) in a report released on Monday. The firm currently has a $1.50 target price on the biotechnology company’s stock.
Several other research firms also recently commented on GNMX. ValuEngine downgraded shares of Aevi Genomic Medicine from a sell rating to a strong sell rating in a research note on Friday, June 2nd. UBS AG reiterated a positive rating on shares of Aevi Genomic Medicine in a research note on Wednesday, May 10th.
Aevi Genomic Medicine (GNMX) remained flat at $1.18 during midday trading on Monday. The company’s stock had a trading volume of 12,747 shares. The firm’s 50-day moving average price is $1.30 and its 200-day moving average price is $2.56. Aevi Genomic Medicine has a 1-year low of $0.98 and a 1-year high of $6.89. The company’s market cap is $43.79 million.
Aevi Genomic Medicine (NASDAQ:GNMX) last posted its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by $0.02. On average, equities research analysts expect that Aevi Genomic Medicine will post ($1.08) earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of GNMX. State Street Corp increased its position in Aevi Genomic Medicine by 15.4% in the fourth quarter. State Street Corp now owns 345,698 shares of the biotechnology company’s stock worth $1,789,000 after buying an additional 46,149 shares in the last quarter. LMR Partners LLP acquired a new position in Aevi Genomic Medicine during the second quarter worth about $149,000. TIAA CREF Investment Management LLC increased its position in Aevi Genomic Medicine by 16.7% in the first quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock worth $182,000 after buying an additional 13,966 shares in the last quarter. Birchview Capital LP increased its position in Aevi Genomic Medicine by 41.7% in the first quarter. Birchview Capital LP now owns 68,000 shares of the biotechnology company’s stock worth $126,000 after buying an additional 20,000 shares in the last quarter. Finally, Teachers Advisors LLC acquired a new position in Aevi Genomic Medicine during the fourth quarter worth about $204,000. Institutional investors own 27.97% of the company’s stock.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.